AB0124 is a serotonin 5-HT2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT2A receptor, with no potentiation of the serotonin 5-HT2B and 5-HT2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT2 receptors. AB0124 has been studied in combination with the serotonin 5-HT2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.
See also 5-HT2A receptor § Positive allosteric modulators JPC0323, CTW0404, and glaucine
References